rethinkPeptides Search
Menu
Study breakdown

Bremelanotide (PT-141) for Female Sexual Dysfunction: Comprehensive Preclinical CNS Mechanism Review

ReviewModerate evidence
The takeaway

This review covers bremelanotide's mechanism for female sexual function: central melanocortin MC3R/MC4R activation in hypothalamic and limbic sexual arousal circuits, with evidence for enhancing desire, arousal, and satisfaction.

Key finding

Bremelanotide activates female sexual function through MC3R/MC4R in hypothalamic/limbic sexual circuits, enhancing desire and arousal through dopamine

What the researchers found

Bremelanotide activates female sexual function through MC3R/MC4R in hypothalamic/limbic sexual circuits, enhancing desire and arousal through dopaminergic and oxytocinergic pathway modulation — the comprehensive CNS mechanism supporting its clinical development for female HSDD.

Why it matters

Relevant for pt-141, melanotan, sexual-health.

How the study worked

review study on pt-141, melanotan.

What this study cannot tell us

See abstract.

How to read the evidence

moderate evidence.

When this study was published

Published in 2007.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
Bremelanotide (PT-141) for Female Sexual Dysfunction: Comprehensive Preclinical CNS Mechanism Review
What was found?
This review covers bremelanotide's mechanism for female sexual function: central melanocortin MC3R/MC4R activation in hypothalamic and limbic sexual arousal circuits, with evidence for enhancing desire, arousal, and satisfaction.

Read the original research

Bremelanotide: an overview of preclinical CNS effects on female sexual function.

The journal of sexual medicine, 4 Suppl 4, 269-79

Citation

Pfaus, James; Giuliano, François; Gelez, Hélène. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function.. The journal of sexual medicine, 4 Suppl 4, 269-79.